Liuyun Wu

Liuyun Wu

Auto-generated profile, based on publicly available information

Liuyun Wu

Affiliation Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Phytomedicine
Verified
Journal Article
Closed access
LHLizhu Han
Lizhu Han
LWLiuyun Wu
Liuyun Wu
QYQinan Yin
Qinan Yin
LLLian Li
Lian Li
XZXingyue Zheng
Xingyue Zheng
YBYuan Bian
Yuan Bian

11 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FKFengjiao Kang
Fengjiao Kang
YWYin Wang
Yin Wang
FCFengqun Cai
Fengqun Cai
LWLiuyun Wu
Liuyun Wu
LHLizhu Han
Lizhu Han
YBYuan Bian
Yuan Bian
Fondaparinux is a widely used anticoagulant for treating venous thromboembolism and acute coronary syndrome by inhibiting factor Xa. However, it carries a risk of bleeding. This study analyzes its safety using the FDA Adverse Event Reporting System (FAERS) database to guide clinical use and future research. Data from 2004 Q1 to 2024 Q3 were examined using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) methods. Among 21,483,491 reports, 5,788 were related to fondaparinux, with 17,523 adverse events (AEs). The most affected systems were vascular (n = 2046) and blood/lymphatic (n = 1125). Abnormal coagulation factor X concentration, thrombosis with thrombocytopenia syndrome, and incision site hematoma had the strongest signals. AEs were more frequent in females and elderly patients, especially within the first month. Additional Preferred Term (PT)–level signals defined in MedDRA were observed, including heparin induced thrombocytopenia and eosinophilia. Heightened pharmacovigilance particularly in older adults may be warranted. This study enhances understanding of fondaparinux’s safety, providing insights for reducing risks and ensuring safer clinical application.